13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • PROOF

    Acronym: 

    PROOF

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Other
    Trial Type Treatment
    Phase Phase III Tumour Stream Cholangiocarcinoma
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Other
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Cholangiocarcinoma
    Cancer Stage
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Phase III multicenter, open-label, randomised, controlled study of oral infigratinib vs. gemcitabine with cisplatin in subjects with advanced/ metastatic or inoperable cholangiocarcinoma with FGFR2 gene fusions/ translocations

    Lay Summary

    Sponsor / Cooperative group

    PPD/QED Therapeutics

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Nimit Singhal Not Yet Recruiting